



11 May 2016

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**cyclo**medica  
**techneg**as  
**ultra**lute

Cyclopharm Ltd  
ABN 74 116 931 250  
Bldg 75 Business & Technology Park  
New Illawarra Road  
Lucas Heights NSW 2234 Australia  
POB 350 Menai Central NSW 2234  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

## **BOARD CHANGE EFFECTIVE AFTER THE ANNUAL GENERAL MEETING**

Cyclopharm Limited (ASX: CYC) advises that Mr Henry Townsing did not seek re-election as a director at today's Annual General Meeting. The Board would like to thank Mr Townsing for his contribution to the Company and wishes him well in his future endeavours.

A copy of the Appendix 3Z Final Director's Interest Notice is enclosed.

For more information, please contact:

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

---

### **Background**

#### **Cyclopharm Limited**

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

#### **Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700°C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).



## **Ultralute™**

Ultralute™ is a unique device that extends the useful life of Molybdenum-99 generators by up to 50 per cent. Molybdenum-99 decays into Technetium-99m, which is used in approximately 80% of all nuclear medicine diagnostic imaging procedures worldwide or an estimated 20 million diagnostic procedures per year. Ultralute™ attaches to the top of the generator and allows the nuclear medicine clinician to retrieve a smaller, more highly concentrated sample of Technetium-99m.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cyclopharm Limited</b>
<b>ABN</b>	<b>74 116 931 250</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Henry Townsing
<b>Date of last notice</b>	26 November 2015
<b>Date that director ceased to be director</b>	11 May 2016

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil

+ See chapter 19 for defined terms.

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest	
Nil	

#### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	Nil
<b>Name of registered holder (if issued securities)</b>	Nil
<b>No. and class of securities to which interest relates</b>	Nil

---

+ See chapter 19 for defined terms.